Vanoxerine (dihydrochloride)

Vanoxerine dihydrochloride (GBR-12909 dihydrochloride) is a competitive, potent, and highly selective dopamine reuptake inhibitor (Ki=1 nM) . Vanoxerine dihydrochloride (GBR-12909 dihydrochloride) binds to the target site on the dopamine transporter (DAT) [1].

Product Specifications

CAS Number

[67469-78-7]

Product Name Alternative

GBR-12909 dihydrochloride; I893 dihydrochloride

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Dopamine Transporter

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Vanoxerine-dihydrochloride.html

Purity

99.60

Solubility

DMSO : 9.4 mg/mL (ultrasonic; warming) |H2O : 1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

FC1=CC=C(C(C2=CC=C(F)C=C2)OCCN3CCN(CCCC4=CC=CC=C4)CC3)C=C1.[2HCl]

Molecular Formula

C28H34Cl2F2N2O

Molecular Weight

523.49

Precautions

H302, H315, H319, H335

References & Citations

[1]Rothman RB, et al. Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol. 2008 Jan 1;75 (1) :2-16.|[2]Andersen PH. The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol.|[3]Hirate K, et al. Characteristics of the ambulation-increasing effect of GBR-12909, a selective dopamine uptakeinhibitor, in mice. Jpn J Pharmacol. 1991 Apr;55 (4) :501-11.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Phase 3

Citation 01

BioRxiv. 2024 Dec 23:2024.12.22.629999.|Nature. 2024 Aug;632 (8025) :686-694.|University of Groningen. 2016 Jun 1.|Biochem Biophys Res Commun. 2020 May 14;525 (4) :989-996.|Cell. 2025 Oct 24:S0092-8674 (25) 01131-6.|Front Cell Neurosci. 2018 Sep 11:12:309.|Neuron. 2023 May 17;111 (10) :1626-1636.e6.